Zacks: Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Quarterly Sales of $75.70 Million

Wall Street brokerages expect that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will report sales of $75.70 million for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Neurocrine Biosciences’ earnings, with the lowest sales estimate coming in at $57.00 million and the highest estimate coming in at $84.60 million. The firm is scheduled to report its next quarterly earnings results on Tuesday, February 13th.

According to Zacks, analysts expect that Neurocrine Biosciences will report full year sales of $75.70 million for the current year, with estimates ranging from $65.10 million to $151.67 million. For the next year, analysts forecast that the firm will report sales of $313.38 million per share, with estimates ranging from $196.30 million to $511.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same period last year, the company earned ($0.43) earnings per share.

A number of brokerages recently issued reports on NBIX. BMO Capital Markets increased their price target on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the stock an “outperform” rating in a report on Friday, August 4th. Oppenheimer Holdings, Inc. increased their price target on shares of Neurocrine Biosciences from $70.00 to $85.00 and gave the stock an “outperform” rating in a report on Thursday, November 2nd. Piper Jaffray Companies set a $68.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Thursday, August 24th. Citigroup Inc. reissued a “buy” rating and set a $79.00 price target on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Finally, Needham & Company LLC reissued a “buy” rating and set a $86.00 price target on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $78.88.

Shares of Neurocrine Biosciences (NASDAQ:NBIX) opened at $75.46 on Monday. Neurocrine Biosciences has a twelve month low of $37.35 and a twelve month high of $75.98. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37.

WARNING: “Zacks: Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Quarterly Sales of $75.70 Million” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/11/13/zacks-analysts-expect-neurocrine-biosciences-inc-nbix-will-post-quarterly-sales-of-75-70-million.html.

In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 26,250 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $1,575,000.00. Following the completion of the sale, the insider now directly owns 144,601 shares in the company, valued at $8,676,060. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Christopher Flint Obrien sold 52,817 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $57.50, for a total transaction of $3,036,977.50. Following the sale, the insider now owns 101,790 shares of the company’s stock, valued at $5,852,925. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 110,810 shares of company stock valued at $6,797,998. 4.80% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN increased its position in shares of Neurocrine Biosciences by 14.5% during the third quarter. Wells Fargo & Company MN now owns 945,368 shares of the company’s stock valued at $57,931,000 after acquiring an additional 119,383 shares during the last quarter. Schroder Investment Management Group increased its position in shares of Neurocrine Biosciences by 81.0% during the third quarter. Schroder Investment Management Group now owns 37,105 shares of the company’s stock valued at $2,204,000 after acquiring an additional 16,609 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of Neurocrine Biosciences during the third quarter valued at about $246,000. Legal & General Group Plc increased its position in shares of Neurocrine Biosciences by 14.6% during the third quarter. Legal & General Group Plc now owns 36,497 shares of the company’s stock valued at $2,237,000 after acquiring an additional 4,638 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Neurocrine Biosciences during the third quarter valued at about $1,457,000.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply